Julian Baker’s Aligos Therapeutics ALGS Stock Holding History

Julian Baker’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$479K	Hold	83,055	–	–	﹤0.01%	82
2026 Q1	$617K	Hold	83,055	–	–	﹤0.01%	82
2025 Q4	$774K	Hold	83,055	–	–	﹤0.01%	83
2025 Q3	$814K	Hold	83,055	–	–	0.01%	86
2025 Q2	$599K	Hold	83,055	–	–	0.01%	85
2025 Q1	$685K	Hold	83,055	–	–	0.01%	83
2024 Q4	$3.31M	Hold	83,055	–	–	0.04%	78
2024 Q3	$719K	Sell	83,055 -1	-0%	-$12	0.01%	87
2024 Q2	$727K	Hold	83,056	–	–	0.01%	89
2024 Q1	$2.03M	Hold	83,056	–	–	0.03%	74
2023 Q4	$1.38M	Hold	83,056	–	–	0.02%	74
2023 Q3	$1.55M	Hold	83,056	–	–	0.01%	92
2023 Q2	$2.02M	Hold	83,056	–	–	0.01%	94
2023 Q1	$1.81M	Hold	83,056	–	–	0.01%	93
2022 Q4	$1.98M	Hold	83,056	–	–	0.01%	98
2022 Q3	$2.28M	Hold	83,056	–	–	0.02%	99
2022 Q2	$2.51M	Hold	83,056	–	–	0.01%	92
2022 Q1	$4.46M	Hold	83,056	–	–	0.03%	87
2021 Q4	$24.6M	Hold	83,056	–	–	0.12%	51
2021 Q3	$32.2M	Buy	83,056 +18,656	+29%	+$7.38M	0.14%	49
2021 Q2	$32.8M	Hold	64,400	–	–	0.14%	51
2021 Q1	$36.6M	Hold	64,400	–	–	0.16%	51
2020 Q4	$44.5M	Buy	+64,400	New	+$31.4M	0.17%	37

Other funds holding ALGS

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Julian Baker's ALGS Position: Q2 2026 in Review

Julian Baker held its Aligos Therapeutics (ALGS) position steady in Q2 2026 at 83,055 shares worth $479K. The position accounts for ﹤0.01% of the portfolio, ranked #82.

Julian Baker first reported a position in ALGS in Q4 2020 and has held it in 23 quarters since. The position peaked at $44.5M in Q4 2020. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

Julian Baker held 83,055 shares of Aligos Therapeutics worth $479K as of Q2 2026.
Julian Baker left its Aligos Therapeutics share count unchanged in Q2 2026.
Aligos Therapeutics made up ﹤0.01% of Julian Baker's portfolio in Q2 2026, its #82 holding.
Julian Baker first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 23 quarters since.
Julian Baker's Aligos Therapeutics position peaked at $44.5M in Q4 2020.
31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.